As the drug’s developers promised in a recent interview with Meduza, we now have a peer-reviewed scientific article that makes the case for EpiVacCorona, Russia’s latest coronavirus vaccine. Though the research didn’t arrive until March 25, the drug itself won regulatory approval back in October 2020 and has been available to Russian patients outside clinical trials for months. Until yesterday, the only public information about the vaccine was limited to two patents, several statements by Russia’s consumer protection agency (which controls the institute that developed EpiVacCorona), and a few interviews with the drug’s creators. Unfortunately, the long-awaited evidence leaves much to be desired. Notably, scientists released the article in a little-known Russian journal called Infection and Immunity, despite indications from health officials that the research would appear in a more authoritative outlet like The New English Journal of Medicine or The Lancet (which published the first peer-reviewed evidence for the “Sputnik V” vaccine). Meduza reviewed the EpiVacCorona article and asked three experts to assess its strengths and weaknesses.